That's a great presentation. There's a lot going on and it is all highly promising. There's real progress in for instance the RAD 301 imaging diagnostic. The human benefits from monitoring the likes of pancreatic cancer can't be understated and trivehexin seems to beat the current standard. It's interesting that the company is presenting figures on the potential markets for its imaging compounds.
Ann: Investor Presentation, page-2
Add RAD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
-0.001(3.03%) |
Mkt cap ! $14.73M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.3¢ | 3.2¢ | $11.29K | 345.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32394 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 445714 | 1 |
View Market Depth
| Last trade - 15.56pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.2¢ |
Change
-0.001 ( 5.88 %) |
||||
| Open | High | Low | Volume | ||
| 3.2¢ | 3.5¢ | 3.2¢ | 111100 | ||
| Last updated 15.56pm 31/05/2024 ? | |||||
| RAD (ASX) Chart |